Reported Earnings • May 05
First quarter 2026 earnings released: EPS: PK₨3.06 (vs PK₨3.04 in 1Q 2025) First quarter 2026 results: EPS: PK₨3.06 (up from PK₨3.04 in 1Q 2025). Revenue: PK₨6.85b (down 4.3% from 1Q 2025). Net income: PK₨857.2m (flat on 1Q 2025). Profit margin: 13% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 22
AGP Limited to Report Q1, 2026 Results on Apr 29, 2026 AGP Limited announced that they will report Q1, 2026 results on Apr 29, 2026 Valuation Update With 7 Day Price Move • Apr 10
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to PK₨198, the stock trades at a trailing P/E ratio of 14.8x. Average forward P/E is 19x in the Pharmaceuticals industry in Pakistan. Total returns to shareholders of 294% over the past three years. Upcoming Dividend • Apr 03
Upcoming dividend of PK₨6.00 per share Eligible shareholders must have bought the stock before 10 April 2026. Payment date: 12 May 2026. Payout ratio is a comfortable 60% and this is well supported by cash flows. Trailing yield: 4.7%. Lower than top quartile of Pakistani dividend payers (8.9%). In line with average of industry peers (4.6%). Announcement • Mar 30
AGP Limited Proposes Final Dividend for the Year 2025 AGP Limited at the AGM to be held on April 20, 2026 proposed to consider and approve the payment of final dividend at the rate of PKR 6.00 per share (i.e. 60%) as recommended by the Board of Directors. Reported Earnings • Mar 27
Full year 2025 earnings released: EPS: PK₨13.34 (vs PK₨9.54 in FY 2024) Full year 2025 results: EPS: PK₨13.34 (up from PK₨9.54 in FY 2024). Revenue: PK₨28.9b (up 15% from FY 2024). Net income: PK₨3.74b (up 40% from FY 2024). Profit margin: 13% (up from 11% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 49% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Mar 25
AGP Limited, Annual General Meeting, Apr 20, 2026 AGP Limited, Annual General Meeting, Apr 20, 2026. Location: at ramada karachi creek, zulfiqar street 1, dha phase viii, karachi Pakistan New Risk • Mar 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Pakistani stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (64% net debt to equity). Share price has been volatile over the past 3 months (8.2% average weekly change). Announcement • Mar 12
AGP Limited to Report Fiscal Year 2025 Results on Mar 19, 2026 AGP Limited announced that they will report fiscal year 2025 results at 9:30 AM, Pakistan Standard Time on Mar 19, 2026 Announcement • Jan 02
Agp Limited Appoints of Muhammad Asad Khan as Company Secretary, Effective January 01, 2026 AGP Limited in its meeting held on January 01, 2026 announced appointment of Mr. Muhammad Asad Khan as Company Secretary, Effective January 01, 2026. Reported Earnings • Oct 25
Third quarter 2025 earnings released: EPS: PK₨3.72 (vs PK₨2.47 in 3Q 2024) Third quarter 2025 results: EPS: PK₨3.72 (up from PK₨2.47 in 3Q 2024). Revenue: PK₨7.62b (up 27% from 3Q 2024). Net income: PK₨1.04b (up 51% from 3Q 2024). Profit margin: 14% (up from 12% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Sep 03
Second quarter 2025 earnings released: EPS: PK₨2.20 (vs PK₨1.36 in 2Q 2024) Second quarter 2025 results: EPS: PK₨2.20 (up from PK₨1.36 in 2Q 2024). Revenue: PK₨5.56b (down 2.9% from 2Q 2024). Net income: PK₨617.0m (up 62% from 2Q 2024). Profit margin: 11% (up from 6.7% in 2Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 27% per year whereas the company’s share price has increased by 32% per year. New Risk • Aug 27
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.1% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks High level of debt (61% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Buy Or Sell Opportunity • Jul 28
Now 22% overvalued Over the last 90 days, the stock has fallen 4.1% to PK₨198. The fair value is estimated to be PK₨163, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 29% over the last 3 years. Earnings per share has grown by 17%. Buy Or Sell Opportunity • Jul 07
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 3.8% to PK₨197. The fair value is estimated to be PK₨163, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 29% over the last 3 years. Earnings per share has grown by 17%. Buy Or Sell Opportunity • Jun 10
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 4.1% to PK₨199. The fair value is estimated to be PK₨163, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 29% over the last 3 years. Earnings per share has grown by 17%. New Risk • May 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Pakistani stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (61% net debt to equity). Share price has been volatile over the past 3 months (7.3% average weekly change). Valuation Update With 7 Day Price Move • May 08
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to PK₨150, the stock trades at a trailing P/E ratio of 13.4x. Average forward P/E is 18x in the Pharmaceuticals industry in Pakistan. Total returns to shareholders of 99% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at PK₨163 per share. Reported Earnings • May 04
First quarter 2025 earnings released: EPS: PK₨3.04 (vs PK₨1.48 in 1Q 2024) First quarter 2025 results: EPS: PK₨3.04 (up from PK₨1.48 in 1Q 2024). Revenue: PK₨7.16b (up 68% from 1Q 2024). Net income: PK₨852.5m (up 107% from 1Q 2024). Profit margin: 12% (up from 9.7% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Mar 20
Upcoming dividend of PK₨4.00 per share Eligible shareholders must have bought the stock before 27 March 2025. Payment date: 02 May 2025. Payout ratio is a comfortable 42% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of Pakistani dividend payers (9.5%). In line with average of industry peers (2.2%). Reported Earnings • Mar 04
Full year 2024 earnings released: EPS: PK₨9.53 (vs PK₨5.59 in FY 2023) Full year 2024 results: EPS: PK₨9.53 (up from PK₨5.59 in FY 2023). Revenue: PK₨25.0b (up 34% from FY 2023). Net income: PK₨2.67b (up 71% from FY 2023). Profit margin: 11% (up from 8.4% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Mar 03
AGP Limited, Annual General Meeting, Apr 10, 2025 AGP Limited, Annual General Meeting, Apr 10, 2025. Location: karachi Pakistan Announcement • Mar 01
AGP Limited announces Annual dividend, payable on May 02, 2025 AGP Limited announced Annual dividend of PKR 4.0000 per share payable on May 02, 2025, ex-date on March 27, 2025 and record date on April 02, 2025. Reported Earnings • Nov 02
Third quarter 2024 earnings released: EPS: PK₨2.47 (vs PK₨1.21 in 3Q 2023) Third quarter 2024 results: EPS: PK₨2.47 (up from PK₨1.21 in 3Q 2023). Revenue: PK₨6.01b (up 24% from 3Q 2023). Net income: PK₨690.2m (up 104% from 3Q 2023). Profit margin: 12% (up from 7.0% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 5% per year. Reported Earnings • Aug 31
Second quarter 2024 earnings released: EPS: PK₨1.36 (vs PK₨0.99 in 2Q 2023) Second quarter 2024 results: EPS: PK₨1.36 (up from PK₨0.99 in 2Q 2023). Revenue: PK₨5.72b (up 37% from 2Q 2023). Net income: PK₨381.8m (up 37% from 2Q 2023). Profit margin: 6.7% (up from 6.6% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 5% per year. Announcement • Aug 21
AGP Limited to Report First Half, 2024 Results on Aug 27, 2024 AGP Limited announced that they will report first half, 2024 results on Aug 27, 2024 Valuation Update With 7 Day Price Move • May 09
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to PK₨94.26, the stock trades at a trailing P/E ratio of 16.4x. Average forward P/E is 18x in the Pharmaceuticals industry in Pakistan. Total loss to shareholders of 5.1% over the past three years. Reported Earnings • May 04
First quarter 2024 earnings released: EPS: PK₨1.43 (vs PK₨1.27 in 1Q 2023) First quarter 2024 results: EPS: PK₨1.43 (up from PK₨1.27 in 1Q 2023). Revenue: PK₨5.92b (up 52% from 1Q 2023). Net income: PK₨400.3m (up 12% from 1Q 2023). Profit margin: 6.8% (down from 9.1% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 9% per year, which means it is performing significantly worse than earnings. Reported Earnings • Mar 01
Full year 2023 earnings released: EPS: PK₨5.59 (vs PK₨5.61 in FY 2022) Full year 2023 results: EPS: PK₨5.59 (down from PK₨5.61 in FY 2022). Revenue: PK₨18.7b (up 30% from FY 2022). Net income: PK₨1.57b (flat on FY 2022). Profit margin: 8.4% (down from 11% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Feb 21
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to PK₨78.59, the stock trades at a trailing P/E ratio of 14.7x. Average forward P/E is 17x in the Pharmaceuticals industry in Pakistan. Total loss to shareholders of 31% over the past three years. Reported Earnings • Nov 04
Third quarter 2023 earnings released: EPS: PK₨1.21 (vs PK₨0.90 in 3Q 2022) Third quarter 2023 results: EPS: PK₨1.21 (up from PK₨0.90 in 3Q 2022). Revenue: PK₨4.85b (up 45% from 3Q 2022). Net income: PK₨338.7m (up 34% from 3Q 2022). Profit margin: 7.0% (down from 7.6% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 30
Second quarter 2023 earnings released: EPS: PK₨0.99 (vs PK₨0.84 in 2Q 2022) Second quarter 2023 results: EPS: PK₨0.99 (up from PK₨0.84 in 2Q 2022). Revenue: PK₨4.19b (up 21% from 2Q 2022). Net income: PK₨278.1m (up 19% from 2Q 2022). Profit margin: 6.6% (down from 6.8% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 30
First quarter 2023 earnings released: EPS: PK₨1.27 (vs PK₨1.98 in 1Q 2022) First quarter 2023 results: EPS: PK₨1.27 (down from PK₨1.98 in 1Q 2022). Revenue: PK₨3.90b (up 6.5% from 1Q 2022). Net income: PK₨356.1m (down 36% from 1Q 2022). Profit margin: 9.1% (down from 15% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Upcoming Dividend • Apr 03
Upcoming dividend of PK₨2.00 per share at 3.7% yield Eligible shareholders must have bought the stock before 10 April 2023. Payment date: 15 May 2023. Payout ratio is a comfortable 42% but the company is paying out more than the cash it is generating. Trailing yield: 3.7%. Lower than top quartile of Pakistani dividend payers (13%). Lower than average of industry peers (6.1%). Price Target Changed • Feb 28
Price target decreased by 10% to PK₨103 Down from PK₨114, the current price target is an average from 2 analysts. New target price is 81% above last closing price of PK₨56.73. Stock is down 32% over the past year. The company posted earnings per share of PK₨6.24 last year. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director Zafar Sobani was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 30
Third quarter 2022 earnings released: EPS: PK₨0.90 (vs PK₨1.22 in 3Q 2021) Third quarter 2022 results: EPS: PK₨0.90 (down from PK₨1.22 in 3Q 2021). Revenue: PK₨3.34b (up 46% from 3Q 2021). Net income: PK₨253.1m (down 26% from 3Q 2021). Profit margin: 7.6% (down from 15% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Price Target Changed • Apr 27
Price target decreased to PK₨105 Down from PK₨142, the current price target is provided by 1 analyst. New target price is 21% above last closing price of PK₨86.93. Stock is down 20% over the past year. The company posted earnings per share of PK₨5.67 last year. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director Zafar Sobani was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Upcoming Dividend • Apr 08
Upcoming dividend of PK₨2.50 per share Eligible shareholders must have bought the stock before 15 April 2022. Payment date: 20 May 2022. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of Pakistani dividend payers (10%). Lower than average of industry peers (4.0%). Price Target Changed • Mar 30
Price target decreased to PK₨105 Down from PK₨142, the current price target is provided by 1 analyst. New target price is 21% above last closing price of PK₨87.07. Stock is down 24% over the past year. The company posted earnings per share of PK₨5.67 last year. Reported Earnings • Oct 30
Third quarter 2021 earnings released: EPS PK₨1.22 (vs PK₨1.48 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: PK₨2.29b (up 26% from 3Q 2020). Net income: PK₨342.2m (down 17% from 3Q 2020). Profit margin: 15% (down from 23% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 8% per year. Valuation Update With 7 Day Price Move • Sep 13
Investor sentiment improved over the past week After last week's 24% share price gain to PK₨143, the stock trades at a trailing P/E ratio of 25x. Average forward P/E is 20x in the Pharmaceuticals industry in Pakistan. Total returns to shareholders of 70% over the past three years. Reported Earnings • Aug 27
Second quarter 2021 earnings released: EPS PK₨1.39 (vs PK₨1.14 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: PK₨2.01b (up 42% from 2Q 2020). Net income: PK₨388.6m (up 21% from 2Q 2020). Profit margin: 19% (down from 23% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 9% per year. Valuation Update With 7 Day Price Move • Jul 02
Investor sentiment improved over the past week After last week's 17% share price gain to PK₨126, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 15x in the Pharmaceuticals industry in Pakistan. Total returns to shareholders of 54% over the past three years. Reported Earnings • May 02
First quarter 2021 earnings released: EPS PK₨1.37 (vs PK₨1.55 in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: PK₨1.64b (down 6.5% from 1Q 2020). Net income: PK₨383.6m (down 12% from 1Q 2020). Profit margin: 23% (down from 25% in 1Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 5% per year. Upcoming Dividend • Apr 10
Upcoming dividend of PK₨1.00 per share Eligible shareholders must have bought the stock before 16 April 2021. Payment date: 18 May 2021. Trailing yield: 1.8%. Lower than top quartile of Pakistani dividend payers (8.7%). Lower than average of industry peers (3.5%). Reported Earnings • Apr 08
Full year 2020 earnings released The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: PK₨6.95b (up 11% from FY 2019). Net income: PK₨1.59b (up 9.8% from FY 2019). Profit margin: 23% (in line with FY 2019). Post-clinical trial products Launched (during full year): 4 Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 6% per year. Upcoming Dividend • Apr 05
Upcoming dividend of PK₨1.00 per share Eligible shareholders must have bought the stock before 12 April 2021. Payment date: 11 May 2021. Trailing yield: 1.8%. Lower than top quartile of Pakistani dividend payers (8.9%). Lower than average of industry peers (3.5%). Is New 90 Day High Low • Mar 10
New 90-day low: PK₨110 The company is down 7.0% from its price of PK₨119 on 10 December 2020. The Pakistani market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. Reported Earnings • Feb 28
Full year 2020 earnings released: EPS PK₨5.67 (vs PK₨5.17 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: PK₨6.95b (up 11% from FY 2019). Net income: PK₨1.59b (up 9.8% from FY 2019). Profit margin: 23% (in line with FY 2019). Is New 90 Day High Low • Jan 25
New 90-day high: PK₨125 The company is up 15% from its price of PK₨109 on 27 October 2020. The Pakistani market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Is New 90 Day High Low • Dec 09
New 90-day high: PK₨118 The company is up 2.0% from its price of PK₨117 on 10 September 2020. The Pakistani market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. Upcoming Dividend • Nov 04
Upcoming Dividend of PK₨1.00 Per Share Will be paid on the 4th of December to those who are registered shareholders by the 11th of November. The trailing yield of 3.8% is below the top quartile of Pakistani dividend payers (7.8%), but it is higher than industry peers (2.4%). Reported Earnings • Oct 31
Third quarter earnings released Over the last 12 months the company has reported total profits of PK₨1.55b, up 18% from the prior year. Total revenue was PK₨6.68b over the last 12 months, up 13% from the prior year. Is New 90 Day High Low • Sep 28
New 90-day low: PK₨106 The company is down 3.0% from its price of PK₨110 on 30 June 2020. The Pakistani market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 18% over the same period.